Assertio Holdings, INC

Assertio Holdings has completed its acquisition by Zydus Worldwide DMCC in an all-cash transaction valued at $23.50 per share.

Assertio Holdings, Inc. announced a definitive agreement to be acquired by Zydus Worldwide DMCC through a cash tender offer of $23.50 per share.

Assertio Holdings, Inc. announced a definitive agreement with Zydus Worldwide DMCC to be acquired for $23.50 per share in an all-cash tender offer, totaling approximately $166.4 million.

Assertio Holdings and Garda Therapeutics have mutually agreed to postpone the tender offer for Assertio's shares and convertible notes to May 14, 2026.

Assertio Holdings stockholders approved an increase in shares for the 2014 Omnibus Incentive Plan and elected six directors at the 2026 Annual Meeting.

Assertio Holdings and Garda Therapeutics mutually agree to postpone the tender offer commencement to May 8, 2026, impacting the acquisition timeline.

Assertio Holdings reported a net loss of $18.9 million for Q1 2026 while finalizing a $21.80 per share acquisition agreement with Garda Therapeutics.

Assertio Holdings, Inc. reported a net income of $11.4 million for Q3 2025, driven by strong ROLVEDON sales, but anticipates no material ROLVEDON sales in the next two quarters due to integration efforts.

Assertio Holdings, Inc. reported a significantly wider net loss for the second quarter and first half of 2025, driven by strategic divestitures and ongoing legal expenses, despite some product sales growth.

Assertio Holdings' Q1 2025 results reveal a revenue decrease due to generic competition and pricing pressures, alongside a strategic divestiture of Assertio Therapeutics to streamline operations.

Assertio Holdings experienced a decrease in overall revenue for the third quarter of 2024, primarily due to generic competition impacting legacy products, while ROLVEDON sales showed growth.

Assertio Holdings' second quarter results show a net loss, impacted by generic competition for INDOCIN, while ROLVEDON sales continue to grow.

Assertio Holdings reports a comprehensive loss of $30.4 million in 2025, driven by strategic divestitures and ROLVEDON integration efforts, despite increased ROLVEDON sales.

Assertio Holdings, Inc. reports a net product sales of $120.8 million for 2024, driven by ROLVEDON, while navigating generic competition and strategic shifts.

Assertio Holdings' 2023 annual report reveals a year of strategic shifts, including a significant merger, alongside challenges from generic competition impacting key product revenues.

Director William McKee reports the disposal of all equity holdings following the completion of Assertio Holdings' merger with Zydus Worldwide DMCC.

Assertio Holdings, Inc. executive Sam Schlessinger reports the disposal of all equity holdings following the company's acquisition by Zydus Worldwide DMCC.

Director Sigurd Kirk reports the disposal of all equity holdings following the completion of Assertio Holdings' merger with Zydus Worldwide DMCC.

Director Sravan Kumar Emany reports the disposal of all equity holdings following the completion of Assertio Holdings' merger with Zydus Worldwide DMCC.

Assertio Holdings, Inc. has been acquired by Zydus Worldwide DMCC in an all-cash transaction at $23.50 per share.

CEO Mark L. Reisenauer reports the disposal of all equity holdings following the completion of Assertio Holdings' acquisition by Zydus Worldwide DMCC.

Assertio Holdings, Inc. announced its 2026 Virtual Annual Meeting of Stockholders, set for May 5, 2026, to elect directors, approve an incentive plan amendment, and ratify auditor appointments.

Assertio Holdings will conduct its 2025 Annual Meeting of Stockholders virtually on May 7, 2025, and is seeking stockholder approval for several proposals, including a reverse stock split.

Assertio Holdings is holding its virtual annual meeting on May 23, 2024, to vote on director elections, an incentive plan amendment, executive compensation, and corporate governance matters.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has filed a Schedule 13G indicating they beneficially own 0% of Assertio Holdings, Inc. common stock as of May 29, 2026.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 10.74% of AssertIO Holdings, Inc. common stock as of March 31, 2026.